Incannex Healthcare stock tumbles after filing $100M offering
Investing.com - RBC Capital has lowered its price target on MannKind (NASDAQ:MNKD) to $8.00 from $10.00 while maintaining an Outperform rating on the stock. According to InvestingPro data, the company maintains a "GREAT" financial health score and has demonstrated strong profitability with a 74.6% gross margin.
The adjustment comes as RBC updates its financial models for the company, though the firm believes the current stock price reflects "an overly pessimistic view" of MannKind’s commercial products, particularly regarding Tyvaso DPI royalties.
For the second quarter of 2025, RBC forecasts revenue of $77.0 million, slightly below the consensus estimate of $77.9 million, and earnings per share of $0.05, in line with consensus expectations.
RBC notes that key focus areas for investors should include the performance and outlook for Afrezza, MannKind’s inhaled insulin product, which has shown strong prescription growth and may benefit from potential label expansions, including a pediatric approval.
The firm also highlights that attention will likely center on Tyvaso DPI revenues and outlook following the launch of competitor Liquidia Technologies (NASDAQ:LQDA)’ product Yutrepia.
In other recent news, MannKind Corporation’s Q1 2025 earnings report showed a mixed financial performance. The company exceeded revenue expectations, although its earnings per share (EPS) fell slightly short of forecasts. Meanwhile, H.C. Wainwright has assumed coverage of MannKind with a Buy rating, setting a price target of $9.00. This analysis is based on a discounted cash flow valuation with specific financial assumptions. Additionally, MannKind is preparing to present findings from its INHALE-1 clinical trial at the American Diabetes Association’s upcoming event. The study focuses on the efficacy and safety of Afrezza, an inhaled insulin powder for children with Type 1 diabetes. In other developments, MannKind announced the departure of its Chief Medical (TASE:BLWV) Officer, Burkhard Blank, with a transition plan set in place. Blank will remain as a non-executive employee until August 1, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.